169 related articles for article (PubMed ID: 16513623)
1. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.
van Eerd JE; Vegt E; Wetzels JF; Russel FG; Masereeuw R; Corstens FH; Oyen WJ; Boerman OC
J Nucl Med; 2006 Mar; 47(3):528-33. PubMed ID: 16513623
[TBL] [Abstract][Full Text] [Related]
2. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin.
Vegt E; Wetzels JF; Russel FG; Masereeuw R; Boerman OC; van Eerd JE; Corstens FH; Oyen WJ
J Nucl Med; 2006 Mar; 47(3):432-6. PubMed ID: 16513612
[TBL] [Abstract][Full Text] [Related]
3. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
4. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
Jamar F; Barone R; Mathieu I; Walrand S; Labar D; Carlier P; de Camps J; Schran H; Chen T; Smith MC; Bouterfa H; Valkema R; Krenning EP; Kvols LK; Pauwels S
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):510-8. PubMed ID: 12582815
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of kidney uptake of radiolabeled somatostatin analogs: amino acids or gelofusine?
Rolleman EJ; de Jong M; Valkema R; Kwekkeboom D; Kam B; Krenning EP
J Nucl Med; 2006 Oct; 47(10):1730-1; author reply 1731. PubMed ID: 17015911
[No Abstract] [Full Text] [Related]
6. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
9. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
Rolleman EJ; Forrer F; Bernard B; Bijster M; Vermeij M; Valkema R; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):763-771. PubMed ID: 17146655
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo.
de Jong M; Rolleman EJ; Bernard BF; Visser TJ; Bakker WH; Breeman WA; Krenning EP
J Nucl Med; 1996 Aug; 37(8):1388-92. PubMed ID: 8708781
[TBL] [Abstract][Full Text] [Related]
12. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues.
Melis M; Krenning EP; Bernard BF; Barone R; Visser TJ; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1136-43. PubMed ID: 15912401
[TBL] [Abstract][Full Text] [Related]
13. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose.
Rolleman EJ; Krenning EP; Van Gameren A; Bernard BF; De Jong M
J Nucl Med; 2004 Apr; 45(4):709-13. PubMed ID: 15073269
[TBL] [Abstract][Full Text] [Related]
14. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.
Kwekkeboom DJ; Bakker WH; Kooij PP; Konijnenberg MW; Srinivasan A; Erion JL; Schmidt MA; Bugaj JL; de Jong M; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1319-25. PubMed ID: 11585290
[TBL] [Abstract][Full Text] [Related]
15. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
[TBL] [Abstract][Full Text] [Related]
16. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.
de Jong M; Barone R; Krenning E; Bernard B; Melis M; Visser T; Gekle M; Willnow TE; Walrand S; Jamar F; Pauwels S
J Nucl Med; 2005 Oct; 46(10):1696-700. PubMed ID: 16204720
[TBL] [Abstract][Full Text] [Related]
17. Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotide.
Verwijnen SM; Krenning EP; Valkema R; Huijmans JG; de Jong M
J Nucl Med; 2005 Dec; 46(12):2057-60. PubMed ID: 16330570
[TBL] [Abstract][Full Text] [Related]
18. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Maecke HR; Forssell-Aronsson E
J Nucl Med; 2004 Sep; 45(9):1542-8. PubMed ID: 15347722
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
[TBL] [Abstract][Full Text] [Related]
20. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Breeman WA; van der Wansem K; Bernard BF; van Gameren A; Erion JL; Visser TJ; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):312-5. PubMed ID: 12552352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
